EGFR and glioblastoma: The potential adjuvant application of TNFα-inhibitors by afatinib and pomalidomide was observed to effectively inhibit cell growth in multiple subsets of EGFR-expressing GBM, emphasising that the modulation within the PGRN/TNFR1 signalling axis constitutes a very attractive therapeutic research direction [160,161].